Freshly funded via a $53m series B financing round, France-based ImCheck Therapeutics SAS can now enter the clinic with its lead monoclonal antibody and test its potential to activate gamma delta T-cells that kill malignant tumors, the biotech’s CEO and its chief medical officer told Scrip.
“Our first trial will start early in 2020 withICT01 and is based on comprehensive translational research supporting its potential to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?